NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

An Observational Study to Evaluate the Clinical Effectiveness, Quality of Life, Safety and Tolerability of Tocilizumab (TCZ) in Patients With Rheumatoid Arthritis (RA) in Daily Clinical Practice

NCT02552940

CompletedN/A

Sponsor: Hoffmann-La Roche

Conditions: Rheumatoid Arthritis

Interventions: Tocilizumab

Countries: Belgium, Luxembourg

This observational trial will evaluate the effectiveness, the consistency of evaluation scores, quality of life, safety and tolerability of TCZ administered subcutaneously (SC) in participants with RA in daily clinical practice.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Participants naive to TCZ or who have received TCZ SC treatment within 8 weeks prior to the enrolment visit can be included
* Participants in whom the treating physician has made the decision to commence TCZ SC in accordance with the label and reimbursement criteria

Exclusion Criteria:

* Participants who have received TCZ \>8 weeks prior to the enrolment visit
* Participants who have previously received TCZ SC
* Participants who have received treatment with any investigational agent within 4 weeks before starting treatment with TCZ SC

Locations (22)

Aalst, Belgium
Assebroek, Belgium
Bruges, Belgium
Brussels, Belgium
Brussels, Belgium
Brussels, Belgium
Dendermonde, Belgium
Edegem, Belgium
Genk, Belgium
Genk, Belgium
Gilly (Charleroi), Belgium
Kortrijk, Belgium
Liège, Belgium
Lokeren, Belgium
Mont-godinne, Belgium
Ostend, Belgium
Oudenaarde, Belgium
Sijsele, Belgium
Westmalle, Belgium
Wilrijk, Belgium
Zoersel, Belgium
Luxembourg, Luxembourg